| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gennexlab.com | |
| Market Cap | 368.25 Cr. | |
| Enterprise Value(EV) | 390.11 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.27 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 59.45 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 41.99 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 7.12 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 2.26 | Calculated using Price: 16.08 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 22.90 Cr. | 229,009,534 Shares |
| FaceValue | 1 | |
| About Gennex Laboratories Ltd. | ||
| Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements. | ||
| 1 Day |
|
-1.17% |
| 1 Week |
|
-2.78% |
| 1 Month |
|
-6.51% |
| 3 Month |
|
-13.03% |
| 6 Month |
|
+50.28% |
| 1 Year |
|
+175.34% |
| 2 Year |
|
+113.26% |
| 5 Year |
|
+587.18% |
| 10 Year |
|
+1814.29% |
| 7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 8.74 | 2.67 | 6.77 | 5.34 | 10.71 | 9.39 | 7.95 | |
| Return on Capital Employed (%) | 10.91 | 6.31 | 10.52 | 8.36 | 13.24 | 11.82 | 10.19 | |
| Return on Assets (%) | 5.5 | 1.68 | 4.35 | 3.42 | 6.97 | 6.18 | 4.92 |
| Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 31 | 32 | 34 | 36 | 40 | 44 | 80 | 87 | |
| Non Curr. Liab. | 1 | 1 | 1 | 0 | 0 | 16 | 17 | ||
| Curr. Liab. | 17 | 18 | 17 | 21 | 19 | 24 | 30 | 23 | |
| Minority Int. | 6 | 6 | |||||||
| Equity & Liab. | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 | |
| Non Curr. Assets | 23 | 23 | 23 | 22 | 23 | 21 | 84 | 67 | |
| Curr. Assets | 26 | 28 | 29 | 35 | 36 | 47 | 49 | 65 | |
| Misc. Exp. not W/O | |||||||||
| Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 |
| Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 71 | |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 0 | |
| Total Income | 42 | 45 | 57 | 57 | 60 | 63 | 70 | 71 | |
| Total Expenditure | -37 | -42 | -52 | -52 | -53 | -56 | -61 | -53 | |
| PBIDT | 5 | 3 | 5 | 4 | 7 | 7 | 9 | 17 | |
| Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -3 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | |
| Taxation | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -3 | |
| Exceptional Items | 0 | 0 | 0 | ||||||
| PAT | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 10 | |
| Minority Interest | |||||||||
| Share Associate | |||||||||
| Other Related Items | 0 | 1 | |||||||
| Consolidated Net Profit | 3 | 1 | 2 | 2 | 4 | 4 | 6 | 10 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 3 | 2 | -2 | -1 | 12 | 24 | |
| Cash Fr. Inv. | -1 | -1 | -1 | 0 | 0 | -2 | -38 | |
| Cash Fr. Finan. | 1 | -2 | 1 | 0 | 2 | -2 | 21 | |
| Net Change | 0 | 0 | 2 | -2 | 0 | 8 | 6 | |
| Cash & Cash Eqvt | 1 | 1 | 3 | 1 | 1 | 9 | 15 |
|
Thu, 25 Apr 2024
Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations 2015 Of Gennex Laboratories Limited For The Year Ended March 31 2024 With reference to the above captioned subject matter we are hereby enclosing the Compliance Certificate pursuant to Regulation 7(2) and 7(3) of SEBI (LODR) Regulations 2015 for the year ended March 31 2024 duly signed by the Compliance Officer of the Company and the authorised representative / Director of the Companys Registrar and Share Transfer Agent (RTA) viz. M/s R & D Infotech Private Limited certifying the compliance with the requirements of Regulation 7(2) & 7(3) of the said Regulation.We request you to take the above information on record and acknowledge the receipt of the same. |
|
Thu, 25 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to the captioned subject above pursuant to Regulation 74(5) of SEBI (DP) Regulations 2018 we hereby submit the Certificate received from the M/s R & D Infotech Private Limited Registrar & Transfer Agent (RTA) of the Company for the Quarter ended March 31 2024.We request you to take the above information on record and acknowledge the receipt of the same. |
|
Fri, 29 Mar 2024
Closure of Trading Window Notice is hereby given that in pursuance of SEBI (PIT) Regulations 2015 and Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders the Trading Window for dealing in the securities of the Company shall remain closed from April 01 2024 till 48 hours after the public announcement through Board of Directors in their Meeting held for announcing the Audited Financial Results for the Quarter and Year ended March 31 2024 along with other matters for which Trading Window is required to closed.The Board Meeting date to approve the audited financial results of the Company for the Quarter and Year ending on March 31 2024 will be informed in due course.All Promoters / designated / connected persons are advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.We request you to take the above information on record and acknowledge the receipt of the same. |
| Fri, 26 Apr 2024 |
Closing Below Previous Low
|
High Decrease in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
